Cerenome clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
- Minor: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) Enrollment closed, study ongoing
- Notable: CA2024-LM-001 · Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Primary completion pushed from Oct 2, 2026 to Jul 31, 2027
- Notable: ReSPECT-LM · Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Primary completion date changed from estimate of Dec 21, 2025 to Oct 19, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 2 | |
| Phase 1/2 | 2 |
Disease areas by active trials
Glioma (3) · Glioblastoma (2)
Get alerts when Cerenome's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.